TG Therapeutics (NASDAQ:TGTX) Sets New 52-Week High – Should You Buy?

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $65.35 and last traded at $65.8960, with a volume of 259,927 shares changing hands. The stock had previously closed at $63.38.

TG Therapeutics News Roundup

Investors following TGTX have been watching these news items:

• Positive Sentiment: Third-quarter revenue rose about 61% year over year to $259.9 million, topping analyst expectations, as demand for Briumvi accelerated. The company raised its 2026 revenue guidance to $1 billion, supporting the growth outlook. Zacks: TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up
• Positive Sentiment: Coverage of the earnings call highlighted continued Briumvi growth and the raised revenue forecast, reinforcing the case for expanding commercial sales. Yahoo Finance: Q3 2026 Earnings Call Highlights
• Neutral Sentiment: Despite the stronger outlook, some commentary questions whether TGTX’s share price already reflects much of its growth potential, making valuation a key concern for investors. Yahoo Finance: TG Therapeutics Lifts Revenue Guidance As Investors Ask If The Stock Is Pricey

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. B. Riley Financial lifted their target price on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Zacks Research raised shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $78.00 price objective on shares of TG Therapeutics in a report on Tuesday, September 1st. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Weiss Ratings raised shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.

TG Therapeutics Price Performance

The company has a current ratio of 4.50, a quick ratio of 3.72 and a debt-to-equity ratio of 1.30. The company has a 50 day moving average of $56.39 and a 200-day moving average of $44.99. The firm has a market capitalization of $9.94 billion, a P/E ratio of 99.64, a P/E/G ratio of 2.63 and a beta of 1.89.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.01). The firm had revenue of $259.94 million for the quarter, compared to the consensus estimate of $245.47 million. TG Therapeutics had a return on equity of 18.82% and a net margin of 11.81%. The firm’s quarterly revenue was up 60.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.43 EPS. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 0.94 EPS for the current year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Laurence Charney sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the sale, the director directly owned 168,640 shares in the company, valued at approximately $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.87% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its position in shares of TG Therapeutics by 71.7% during the 1st quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock valued at $48,544,000 after acquiring an additional 610,195 shares during the period. Deutsche Bank AG bought a new position in shares of TG Therapeutics in the second quarter worth $12,937,000. Jupiter Topco LLC bought a new position in shares of TG Therapeutics in the second quarter worth $5,319,000. PDT Partners LLC acquired a new position in TG Therapeutics in the second quarter valued at about $2,285,000. Finally, Man Group plc acquired a new position in TG Therapeutics in the second quarter valued at about $7,273,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.